In vivo tumor imaging using polo-box domain of polo-like kinase 1 targeted peptide.

[1]  P. Conti,et al.  In Vivo Near-Infrared Fluorescence Imaging of Integrin α2β1 in Prostate Cancer with Cell-Penetrating-Peptide–Conjugated DGEA Probe , 2011, The Journal of Nuclear Medicine.

[2]  Fa Liu,et al.  Structural and functional analyses of minimal phosphopeptides targeting the polo-box domain of polo-like kinase 1 , 2009, Nature Structural &Molecular Biology.

[3]  Hiroyuki Osada,et al.  Deficiency in Chromosome Congression by the Inhibition of Plk1 Polo Box Domain-dependent Recognition* , 2009, Journal of Biological Chemistry.

[4]  Young-Seung Kim,et al.  Evaluation of a 99mTc-Labeled Cyclic RGD Tetramer for Noninvasive Imaging Integrin αvβ3-Positive Breast Cancer , 2007 .

[5]  G. Montoya,et al.  Molecular and structural basis of polo-like kinase 1 substrate recognition: Implications in centrosomal localization , 2007, Proceedings of the National Academy of Sciences.

[6]  Kyle A. Emmitte,et al.  In vitro biological activity of a novel small-molecule inhibitor of polo-like kinase 1 , 2007, Molecular Cancer Therapeutics.

[7]  P. Kubes,et al.  Reevaluation of P-Selectin and α4 Integrin as Targets for the Treatment of Experimental Autoimmune Encephalomyelitis1 , 2006, The Journal of Immunology.

[8]  M. Lei,et al.  Normal Cells, but Not Cancer Cells, Survive Severe Plk1 Depletion , 2006, Molecular and Cellular Biology.

[9]  Y. Qu,et al.  Inhibitory effect of Polo-like kinase 1 depletion on mitosis and apoptosis of gastric cancer cells. , 2006, World journal of gastroenterology.

[10]  Klaas Nicolay,et al.  MR molecular imaging and fluorescence microscopy for identification of activated tumor endothelium using a bimodal lipidic nanoparticle , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[11]  S. Kimura,et al.  Intravesical administration of small interfering RNA targeting PLK-1 successfully prevents the growth of bladder cancer. , 2005, The Journal of clinical investigation.

[12]  Ran Guan,et al.  Small interfering RNA-mediated Polo-like kinase 1 depletion preferentially reduces the survival of p53-defective, oncogenic transformed cells and inhibits tumor growth in animals. , 2005, Cancer research.

[13]  P. Fischer,et al.  Progress in the discovery of polo-like kinase inhibitors. , 2005, Current topics in medicinal chemistry.

[14]  Jun Yoshimatsu,et al.  Polo-like kinases (Plks) and cancer , 2005, Oncogene.

[15]  R. Moats,et al.  In vivo Near-Infrared Fluorescence Imaging of Integrin αvβ3 in Brain Tumor Xenografts , 2004, Cancer Research.

[16]  K. Strebhardt,et al.  Cancer inhibition in nude mice after systemic application of U6 promoter-driven short hairpin RNAs against PLK1. , 2004, Journal of the National Cancer Institute.

[17]  Erich A. Nigg,et al.  Polo-like kinases and the orchestration of cell division , 2004, Nature Reviews Molecular Cell Biology.

[18]  Rex Moats,et al.  18F-labeled RGD peptide: initial evaluation for imaging brain tumor angiogenesis. , 2004, Nuclear medicine and biology.

[19]  Michael B. Yaffe,et al.  The Molecular Basis for Phosphodependent Substrate Targeting and Regulation of Plks by the Polo-Box Domain , 2003, Cell.

[20]  Xiaoqi Liu,et al.  Polo-like kinase (Plk)1 depletion induces apoptosis in cancer cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[21]  Joel A Swanson,et al.  Drug delivery strategy utilizing conjugation via reversible disulfide linkages: role and site of cellular reducing activities. , 2003, Advanced drug delivery reviews.

[22]  B. Kronenberger,et al.  Tumor regression by combination antisense therapy against Plk1 and Bcl-2 , 2003, Oncogene.

[23]  Milind Rajopadhye,et al.  Tumor targeting with radiolabeled alpha(v)beta(3) integrin binding peptides in a nude mouse model. , 2002, Cancer research.

[24]  C. Mawrin,et al.  Increased Human Polo-Like Kinase-1 Expression in Gliomas , 2001, Journal of Neuro-Oncology.

[25]  K. Sandvig,et al.  Penetration of protein toxins into cells. , 2000, Current opinion in cell biology.

[26]  S. Zeuzem,et al.  Polo-like kinase1, a new target for antisense tumor therapy. , 2000, Biochemical and biophysical research communications.

[27]  H. Lane,et al.  Antibody microinjection reveals an essential role for human polo-like kinase 1 (Plk1) in the functional maturation of mitotic centrosomes , 1996, The Journal of cell biology.

[28]  David A. Cheresh,et al.  Definition of Two Angiogenic Pathways by Distinct αv Integrins , 1995, Science.

[29]  D. Cheresh,et al.  Requirement of vascular integrin alpha v beta 3 for angiogenesis. , 1994, Science.

[30]  M. Yaffe,et al.  Structural and functional analyses of minimal phosphopeptides targeting the polo-box domain of polo-like kinase 1 , 2011, Nature Structural &Molecular Biology.

[31]  Xiaoyuan Chen,et al.  Evaluation of a (99m)Tc-labeled cyclic RGD tetramer for noninvasive imaging integrin alpha(v)beta3-positive breast cancer. , 2007, Bioconjugate chemistry.

[32]  Ryan Park,et al.  MicroPET and autoradiographic imaging of breast cancer alpha v-integrin expression using 18F- and 64Cu-labeled RGD peptide. , 2004, Bioconjugate chemistry.

[33]  D. Cheresh,et al.  Definition of two angiogenic pathways by distinct alpha v integrins. , 1995, Science.